Catalent

Catalent is a leading Contract Development and Manufacturing Organization (CDMO) specializing in gene therapy solutions. With over 30 years of expertise in biologics, Catalent collaborates with premier gene therapy companies to provide custom development and scalable manufacturing of viral vectors, particularly adeno-associated virus (AAV) vectors, next-generation vaccines, and oncolytic viruses.

Their state-of-the-art facilities encompass over 600,000 square feet dedicated to plasmid and gene therapy, ensuring the capability to support more than 60 ongoing gene therapy programs across various development stages. Catalent's integrated services include process development, CGMP manufacturing, and comprehensive analytical services, designed to meet the diverse needs of their clients. Their advanced platforms, such as the UpTempo™ AAV and CAR-T processes, further enhance their offerings, allowing for innovative therapeutic solutions. As a trusted partner, Catalent is committed to advancing gene therapy and helping clients realize their groundbreaking therapeutic innovations.